Igc Pharma, Inc. · AMEX:IGC
Igc Pharma — Investor Presentation (January 2024)
29 slides from Igc Pharma's investor presentation, January 2024
Slide 1: IGC Pharma Jan 2024
(E IGCPHARMA Jan, 2024 NYSE American: IGC
Slide 2: Safe Harbor
SAFE HARBOR The matters discussed in this presentation include forward-looking statements about the business prospects of IGC Pharma, Inc. Forward- looking statements are often preceded by words such as believes, expects, anticipates, plans, will, goal, may, intends, assumes, or similar expressions.
Slide 3: Company Overview
C OM PANY OVERVIEW • Our focus is treating Alzheimer’s disease (AD) through our growing pipeline of five drug assets • Lead therapeutic candidate IGC-AD1 is currently in a 146- person Phase 2b trial for agitation in dementia due to Alzheimer’s. IGC-AD1 is a CB1r partial agonist that reduces neuroinf
Slide 4: Alzheimer's Disease
ALZHEIM ER’S DISEASE 1 in 9 13.8 65+ M illion yrs. Americans with Americans with Alzheimer’s in Alzheimer’s by 20501 6.7 $1 Trillion 20231 million Expected total expenses for Alzheimer’s and other dementias by 20502 Americans with Alzheimer’s age (65+) (1) References: inAlzheimer’s 20231Association
Slide 5: Investment Highlights
INVESTM ENT HIGHLIGHTS Two Patented and three patent pending investigational drug candidates targeting Alzheimer’s All showing favorable pre-clinical attributes towards Alzheimer’s disease pathology IGC-AD1 is currently in Phase 2B with data milestones expected in mid- 2024 Leading artificial intell
Slide 6: Vertically Integrated Operations
VERTICALLY INTEGRATED OPERATIONS Potomac, MD. Vancouver, WA Colombia India Headquarte cGMP Licensed R&D Accounting rs Manufacturing and facilities and Processing facility Analytics Overcoming Operational Barriers to Entry • Licensed phytocannabinoid grow • Approved licenses facilities • Phase 3-read
Slide 7: AD Pipeline Overview
AD PIPELINE OVERVIEW ASSET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MILESTONE TARGETS neuroinflammation, Topline IGC-AD1 neurotransmitter imbalance, data inflammasome-3 and AD pathology Spring 2024 TARGETS Aβ Tox study data mid TGR-63 PLAQUES 2024 (Early- Moderate Stage Alzheimer’s) TARGETS neuroinflamma
Slide 8: Agitation in Alzheimer's
AGITATION IN ALZHEIMER’S Agitation: excessive motor activity, verbal aggression, or physical aggression that is severe enough to impair personal relationships, social functioning, and/or daily activities1. Agitation starts early in AD and increases in severity as the disease progresses 2 . 4 0 - 8 0
Slide 9: Our Solution
OUR SOLUTION The Promise of IGC-AD1 A patent-protected compound in Phase 2B trials that targets agitation in Alzheimer’s disease Two APIs that target neuroinflammation, neurotransmitter imbalance, CB1r agonism and inflammasome- 3, all implicated in agitation in AD IGC-AD1 can potentially reduce agit
Slide 10: Two APIs That Target Multiple Pathways
TWO APIs THAT TARGET MULTIPLE PATHWAYS Focused on relieving pathological alteration due to agitation in AD Agitation in AD Treatment with IGC- AD1 Deficient in CB1 receptor function increases agitation animals1 ; CB1 activity at earlier AD stages is Partial agonist targets CB1 receptor higher in fun
Slide 11: IGC-AD1 Phase I Trial Completed
IGC-AD1 Safety, Tolerability, Agitation, NPS PHASE I TRIAL C OM PLETED No life-threatening or serious Multiple Ascending Dose (MAD) study to adverse events at any dosing evaluate safety and tolerability of IGC-AD1 in level participants with AD & NPS (Neuropsychiatric Symptoms) using the NPI (Neurops
Slide 12: Results on NPS: Neuropsychiatric Symptoms Measured by NPI Scores
RESULTS ON NPS: NEUROPSYCHIATRIC SYMPTOMS MEASURED BY NPI SCORES Total 35 . NPI 0 * 31. * 30 . 5 Results on NPS: 0 Neuropsychiatric 25 . * Symptoms 0 22. 2 * Measured by NPI 20. Scores Average Total 0 ** Baselin 16. Patients taking IGC-AD1 14. * 0 e Day 15. 8 intervention showed an NPI 0 12.4 15 ove
Slide 13: Agitation Results
AGITATION RESULTS NPI 5. Agitation 0 4. 7 4. 4. 5 4. 3 2 4. 0 3. 5 3.0 3. 0 At three different doses, Average 2. Baselin agitation improved both 5 e Day clinically and NPI 2. 15 0 1.5 statistically (p 1.4 1. 5 <.05) 1. 0 0. 5 Cohort Cohort C ohort 0.0 1 2 3 13
Slide 14: Potential of IGC-AD1 Beyond Agitation: Pre-clinical Results on AD Cell Lines
POTENTIAL OF IGC-AD1 BEYOND AGITATION PRE-CLINICAL RESULTS ON AD CELL LINES Decreased plaques and decreased pTau: • Inhibits the aggregation of amyloid plaque • Reduces phosphorylated tau (pTau) • Enhances mitochondrial function • Non-toxic. Repeated low dosing over 48 hours is non- toxic J. Pineal.
Slide 15: Potential of IGC-AD1 Beyond Agitation: Memory Improved in AD Mouse Model
POTENTIAL OF IGC-AD1 BEYOND AGITATION MEMORY IMPROVED IN AD (APP/PS1) MOUSE MODEL AD model mice dosed with the active ingredient in IGC - AD1 had significantly improved times and fewer errors in a Morris Water Maze test than those in the control group • The maze uses spatial cues for mice to navigat
Slide 16: Ongoing IGC-AD1 Phase II Trial
ON GOING IGC- AD1 PHASE II TRIALDouble Blind, Randomized, Multi Site Placebo Controlled, Phase II protocol seeks to show that IGC-AD1 is effective, compared to placebo, in lowering agitation in participants with Alzheimer’s Objective • Evaluate if IGC-AD1 is superior to placebo in reducing agitation
Slide 17: IGC Pharma at the Forefront of AI-Integrated Pharmaceutical Research
IGC PHARMA AT THE FOREFRONT OF AI- INTEGRATED PHARMACEUTICAL RESEARCH IGC is partnered with leading Artificial Intelligence research center CINFONIA at the University of Los Andes Partnership aims to leverage deep learning algorithms and generative AI to analyze variations in disease signatures amon
Slide 18: TGR-63: A Promising Path-Breaking Molecule
TGR-63 A PROMISING PATH- BREAKING MOLECULE • India-based Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) created the TGR-63 • IGC acquired exclusive rights to TGR-63 from AD DRUG molecule JNCASR researchers in 2022 CANDIDATE 2 • Pre-clinical testing demonstrates that TGR-63 holds T
Slide 19: Naphthalene Monoimides
NAPHTHALENE MONOIMIDES • Naphthalene Monoimides are candidates to modulate A𝛽42 aggregation and associated toxicity. • TGR-63 demonstrated higher capacity to inhibit TGR-63 A𝛽42 aggregation (A), higher capacity to dissolve Aβ42 aggregates (B) and increased PC12 cell viability (C) when compared to…
Slide 20: The Promise of TGR-63: Reduction of Plaque in Mouse Model
The Promise of TGR-63: Reduction of Plaque in MouseTGR-63 Modeleffectively reduced the amyloid burden in the mice cortex and hippocampus. WT DAPI AD +TGR6 +TGR6 DAPI OC 3 DAPI 3 OC Before TGR63 After administration AD/WT administration Behavioral administration Immunohistochemis m 14 m 0 m 6 charact
Slide 21: TGR-63 Improved Behavior in a Mouse Model
TGR-63-Improved Behavior In a Mouse Model TGR-63 improved cognitive performance in APP/PS1 and Wild Type mice. The dose administered was 5 mg/kg body weight. Open field test TGR-63 treated mice had a lower locomotion in the field, indicating improved behavior. Adv. Therap. 2021, 4, 2000225 NYSE Amer
Slide 22: TGR-63 Improved Memory in a Mouse Model
TGR-63 Improved memory in a Mouse Model Novel object Adv. Therap. 2021, 4, 2000225 identification test TGR-63 treated mice had a higher exploration of the novel object. Morris W ater Maze TGR-63 treated mice learned the location of the target and had less error rate than non treated mice.
Slide 23: TGR-63 to IGC-AD2 Timeline
TGR-63 TO “IGC-AD2” TIMELINE Early- Preclinical FDA Review Stage Preclinic Clinical studies and and Post – Drug al Drug Trials M arket Developm studies Development (IGC- Monitoring ent AD2) Target Identified Established Licensing of TGR-63 and validated the Proof of Phase-2 Clinical • New Drug (JNC
Slide 24: First Mover Advantage with Intellectual Property
FIRST MOVER ADVANTAGE WITH INTELLECTUAL PROPERTY FOREIG PATENT US- TARGET DES C RIPTI N APPLIC ATIO PATENTS ON PATENT NS •Alzheimer's Disease (IGC- Composition & Method for treating CNS Disorders 7 1 GRANTE S 1 GRANT •Alzheimer's AD1) Disease (IGC- Composition & Method for treating CNS Disorders D 1
Slide 25: Potential to Drive Significant Value
POTENTIAL TO DRIVE SIGNIFICANT VALUE NORTH AMERICA AND EUROPE ITEM Year 1 Year 2 Year 3 Individuals with AD 15M 15M 15M Agitation in AD (76%) 11M 11M 11M % adoption of drug 3% 5% 10% (IGC- AD1) Annual Price/Patient of $1,200 – $2,400 $1,200 – $2,400 $1,200 – $2,400 drug Estimated $0.4B – $0.8B $0.8B
Slide 26: Senior Scientific Trial Team
SENIOR SCIENTIFIC TRIAL TEAM Dr. Varduhi Ghazaryan, MD, MPH Medical Director Dr. Saadia Shahnawaz, MD Medical Director Dr. Juan Manuel Orjuela, MD Scientific Neuropsychiatrist Manageme Jagadeesh Rao, PhD nt Principal Scientist Diego Rodriguez, PhD Senior Medicinal Chemist Evelyn Gutiérrez, Chem Eng.
Slide 27: Senior Scientific Advisors
SENIOR SCIENTIFIC ADVISORS Prof. Chuanhai Cao, PhD Professor of Pharmaceutical Science Inventor s Prof. T Govindaraju, PhD, FRSC. Professor - Bioorganic Chemistry Dr. L. Elliot Hong, MD Professor Psychiatrist Dr. James Saunders, PhD Ret. Professor, Molecular Scientifi Biology c Jeffrey L. Cummings A
Slide 28: Caregiver Testimonial
Caregiver Testimonial From our Phase 1 IGC - AD1 study “I want to tell you a story that brought incredible joy to me. We participated in your Phase 1 Clinical trial in Puerto Rico. After about a week of medication, one day I came home to find that she had made dinner and was dancing to music that sh
Slide 29: Thank You
THANK YOU igc@imsinvestorrelations.